ArticlePLOS global public health2026
Availability of Hib, Pneumococcal, Rotavirus, and HPV vaccines in China: Implication for equity in access to immunization services.
Article in PLOS global public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Latent profiles of HPV vaccine-related health beliefs and their associations with vaccination intention among college students: a global health perspective.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines are cornerstones of public health, yet equitable access remains a major global challenge. While China has achieved sustained high coverage of National Immunization Program (NIP) vaccines, some WHO-recommended cost-effective non-NIP vaccines, such as Hib, pneumococcal conjugate (PCV), rotavirus, and human papillomavirus vaccines (HPV) are not universally accessible and often require out-of-pocket payment. This study examines geographic and urban-rural disparities in the availability of these four vaccines across China using data from a nationally representative China's National Health Accounts survey in 2022, covering 355 district- and county-level disease control centers and 2,609 public primary health facilities across 27 provinces. Availability was defined as the presence of at least one dose delivered or administered. Inequality was assessed using Slope Index of Inequality (SII) and the Erreygers-corrected Concentration Index (CI), based on provincial GDP per capita. We found significant disparities in vaccine availability across economic development levels and urban-rural settings in China. Overall, HPV vaccines were most available (96.9%) and PCV13 the least (86.5%) at the district/county level. Urban areas had markedly higher availability than rural areas, particularly for PCV13 (94.2% vs. 79.1%). At the clinic level, over 70% of urban clinics provided all four vaccine types, compared to just 40% in rural areas. The vaccines with the highest inequality were DTaP-IPV-Hib (CI: 0.408), PCV13 (CI: 0.362), and RV5 (CI: 0.343), indicating strong pro-rich distribution. In contrast, the Hib vaccine demonstrated the lowest inequality (CI: 0.209). These findings highlight significant inequities in the availability of WHO-recommended non-NIP vaccines across China, particularly affecting rural and economically disadvantaged regions underscoring the need of expanding vaccine provision in underserved areas, strengthening rural service capacity, and considering the inclusion of these vaccines in the NIP.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.